10 Stocks Insiders Spent The Most Money On Recently

6. Metsera, Inc. (NASDAQ:MTSR)

Value Of Shares Acquired: $94,219,956.00

Market Cap: $3.31 billion

Sixth among 10 stocks insiders spent the most money on recently is Metsera, a clinical-stage biotechnology company. Metsera is engaged in the development of injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. The New York City-headquartered company is working on a comprehensive portfolio of therapies with the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.

On February 3, three insiders purchased a total of around $94.22 million worth of Metsera shares during the company’s initial public offering. Insiders acquired shares at a price of $18 per share. The company raised $257 million during its IPO, pricing shares above its targeted range. Currently, the stock is trading at $32.08 per share, having gained 21.06% since then.

In January, the company announced positive data from a 12-week Phase 2a clinical trial of its leading candidate – MET-097i, a potential once-monthly injectable treatment for obesity. The results revealed that MET-0971 helped participants lose weight (with some losing 20% of their body weight), and was well tolerated with mild side effects. The company plans further studies in 2025.

“MET-097i has the potential to be a foundational therapy for people with obesity and overweight, by virtue of its effectiveness, compelling tolerability profile and flexible options for dosing, including titration-free weekly dosing and monthly dosing,” commented John Buse, M.D., Verne S. Caviness Distinguished Professor and Director of the UNC Diabetes Center at University of North Carolina School of Medicine.

Currently, there is no analyst coverage available for this stock as it recently went public and coverage typically begins after a company has been listed for a certain period of time. We should expect analyst reports as the company matures in the market.